BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk
Survodutide, produkta foto
GLP-1

Survodutide

GLP-1

  • Sūtām no Vācijas

Pasūtījums

Vienības cena - Bezmaksas piegāde Vācijā no 200 € Black Weeks laikā
  • DHL ar izsekošanu
  • Diskrēts iepakojums

4.6 no 5 Trustpilot73 atsauksmes

Meklēts arī kā: Survodutid · BI 456906

Īsumā

Survodutide skaitļos

Galvenie rādītāji no mūsu leksikona.

Pilns leksikona ieraksts
Class
GLP-1 / glucagon dual agonist
Half-life
Several daysweekly dose
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
10 mg1 size in the shop
  1. up to~15 %

    Phase 2 study in obesity (dose-dependent, up to ~15% weight reduction at 46 weeks) (opens in a new tab)

    le Roux et al., Lancet Diabetes & Endocrinology, 2024
  2. Phase 2 study in MASH and liver fibrosis (opens in a new tab)

    Sanyal et al., New England Journal of Medicine, 2024
  3. Phase 3 trial SYNCHRONIZE-1 in obesity without diabetes (725 adults, 76 weeks) (opens in a new tab)

    le Roux et al., New England Journal of Medicine, 2026

Produktam Survodutide vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes

Zināšanas

Viss par Survodutide

Noderēs

Kas jums vēl būs vajadzīgs

Bakteriostatiskais ūdens tiek automātiski pievienots grozam. Šļirces un salvetes - ar vienu klikšķi.

Insulīna šļirces

10 gab. · 5.50 €

Spirta salvetes

50 gab. · 10 €

Cik daudz ūdens?

Vienības uz šļirces jūsu flakona izmēram.

Atvērt kalkulatoru →

FAQ

Bieži uzdotie jautājumi

Avoti katrai atbildei: leksikona ieraksts

Vēl ir jautājums?

Rakstiet mums, mūsu komanda jums palīdzēs.

Is Survodutide approved?

No. ChEMBL lists Survodutide with phase 3 as the highest phase. The first phase 3 trials (SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD) are finished and were published in 2026, others are still running. The information here describes the state of research and is not a recommendation for use.

How does Survodutide differ from Semaglutide and Retatrutide?

The receptors. Semaglutide acts only on the GLP-1 receptor, Survodutide also on the glucagon receptor, Retatrutide additionally on GIP. The glucagon part acts mainly in the liver, which is why Survodutide is also tested in fatty liver. In a phase 2 trial in type 2 diabetes the higher levels lowered weight more than semaglutide after 16 weeks.

What did the phase 3 trials show?

In SYNCHRONIZE-1 (without diabetes) weight fell by 12.2 and 13.0 percent after 76 weeks, by 5.4 percent on placebo. In SYNCHRONIZE-2 (with type 2 diabetes) it was 8.2 and 9.8 versus 3.9 percent, HbA1c fell by 0.9 and 0.8 percentage points. In SYNCHRONIZE-MASLD liver fat fell by at least 30 percent in 68.5 percent, on placebo in 28.6 percent.

What is known about the liver?

In a phase 2 trial with biopsy MASH improved without worsening of fibrosis in 43 to 62 percent depending on the dose, in 14 percent on placebo. Fibrosis improved in 34 to 36 versus 22 percent. A study in liver cirrhosis tested uptake and tolerability. Two large phase 3 trials on MASH are still running.

How high were the doses in trials?

The highest study dose was 6 mg per week, in the liver trial and the phase 3 programme. All trials raise the dose in steps over weeks. In the phase 2 trial in overweight the effect rose only a little from the second level on. The entry describes the same principle: start low and only increase until an effect is noticeable. This is not a dosing recommendation.

Which side effects were seen?

Mainly gastrointestinal effects, mostly mild to moderate. In SYNCHRONIZE-1 80.9 and 89.7 percent had them, 47.9 percent on placebo. In the liver trial nausea, diarrhoea and vomiting were clearly more common with Survodutide than with placebo. The trials describe the complaints mainly during escalation.

Which trials are still running?

Three of the listed phase 3 trials are still recruiting: LIVERAGE on MASH with fibrosis (planned end 2031), LIVERAGE-Cirrhosis on MASH with cirrhosis and a trial on blood sugar in type 2 diabetes. The large cardiovascular safety trial with 5,531 participants is finished, results had not been published by October 2026.

Saistītie

Saistītie produkti